Sudarshan Pharma Industries Ltd

BSE: 543828

22

total announcements

543828.BO · 15 min delayed

BSEAGM/EGM5d ago

Sudarshan Pharma Industries Ltd

Please find enclosed the Scrutinizer''s Report on the business transacted at the 18th Annual General Meeting of the company held on Tuesday 22/SEPT/2026 through video conferencing / other audio-visual means.

Sudarshan Pharma Industries Ltd has announced the Scrutinizer's Report on the business transacted at the 18th Annual General Meeting held on September 22, 2026, through video conferencing. The report confirms the voting results for the resolutions set forth in the Notice of AGM.

Read more →📎 1 attachment
BSEAGM/EGMResults5d ago

Sudarshan Pharma Industries Ltd

Please find enclosed the voting results on the business transacted at the 18th Annual General Meeting of the company held on Tuesday 22/SEPT/2026 at 3:00 p.m. through Video Conferencing/ Other Audio Visual Means.

Sudarshan Pharma Industries Ltd has announced the voting results of its 18th Annual General Meeting held on September 22, 2026, through video conferencing. The meeting was conducted in accordance with Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Read more →📎 1 attachment
BSEAGM/EGM5d ago

Sudarshan Pharma Industries Ltd

Pursuant to Regulation 30 of SEBI ( Listing Obligations and Disclosure Requirements ) Regulations, 2015 we enclose herewith the summary of proceedings of the AGM.

Sudarshan Pharma Industries Ltd held its 18th Annual General Meeting on September 22, 2026, through video conferencing. The meeting was chaired by Mr. Hemal V. Lele, Chairman & Managing Director, and discussed the company's financial performance, expansion strategy, and other operations.

Read more →📎 1 attachment
BSEInsider Trading / SASTRelated Party9 Sept 2026

Sudarshan Pharma Industries Ltd

The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 09, 2026 for Hemal V Mehta HUF, Mrs. Devangi Hemal Mehta, Sachin V Mehta HUF and Mrs. Namrata Sachin Mehta

Sudarshan Pharma Industries Ltd has received revised disclosures under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Hemal V Mehta HUF, Mrs. Devangi Hemal Mehta, Sachin V Mehta HUF and Mrs. Namrata Sachin Mehta.

Read more →
BSEInsider Trading / SASTPledge9 Sept 2026

Sudarshan Pharma Industries Ltd

The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 09, 2026 for Hemal Vasantrai Mehta

Sudarshan Pharma Industries Ltd has submitted a revised disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the release of pledge of 20,00,000 equity shares held by Mr. Hemal Vasantrai Mehta, a promoter of the company.

Read more →📎 1 attachment
BSEAGM/EGMResults29 Aug 2026

Sudarshan Pharma Industries Ltd

Pursuant to Regulation 34 of SEBI Listing Regulations, please find enclosed the Notice of 18th Annual General Meeting to be held on Tuesday, 22/September/2026.

Sudarshan Pharma Industries Ltd has announced its 18th Annual General Meeting to be held on September 22, 2026, through video conferencing. The meeting will consider the audited financial statements for the year ended March 31, 2026, and the re-appointment of Dr. Anil Ghogare as a director.

Read more →📎 1 attachment
BSEInsider Trading / SASTPledge26 Aug 2026

Sudarshan Pharma Industries Ltd

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 26, 2026 for Hemal V Mehta & Sachin V Mehta

Sudarshan Pharma Industries Ltd has made a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the creation of a pledge on the company's shares by persons belonging to the promoter category.

Read more →📎 1 attachment
BSEInsider Trading / SASTPledge22 Aug 2026

Sudarshan Pharma Industries Ltd

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 21, 2026 for Hemal V Mehta & Sachin V Mehta

Sudarshan Pharma Industries Ltd has made a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the creation of a pledge on the company's equity shares by persons belonging to the 'Promoter' category.

Read more →📎 1 attachment
BSECompany UpdateFundraise19 Aug 2026

Sudarshan Pharma Industries Ltd

It is hereby informed that the members of the FCCB COmmittee of the COmpany, have at their meeting held today, 19/Aug/2026, have approved allotment of 48,11,730 fully paid-up equity shares ....

Sudarshan Pharma Industries Ltd has approved the allotment of 48,11,730 fully paid-up equity shares upon conversion of Foreign Currency Convertible Bonds (FCCBs) worth USD 15,00,000. The company's capital structure will change with the post-allotment number of shares increasing to 25,44,70,600 and issued and paid-up capital increasing to Rs. 25,44,70,600.

Read more →📎 1 attachment
BSECompany UpdateM&A14 Aug 2026

Sudarshan Pharma Industries Ltd

We hereby submit the presentation on the manufacturing plant proposed to be acquired by the Company.

Sudarshan Pharma Industries Ltd submitted a presentation on the proposed acquisition of a manufacturing plant. The plant is located 40km from Visakhapatnam Airport and spans 14 acres. It is engaged in manufacturing API and API Intermediates, with approvals from DCA, WHO, USFDA, and ANVISA. The facility has a workforce of 200 employees and operates 24/7.

Read more →📎 1 attachment
BSECompany UpdateDivestiture13 Aug 2026

Sudarshan Pharma Industries Ltd

The Board of Directors at their Meeting held on 12/August/2026 approved the divestment of 2,09,100 equity shares (51.00% of paid up share capital) of Ishwari Healthcare Private Limited. ....

Sudarshan Pharma Industries Ltd has approved the divestment of 2,09,100 equity shares (51.00% of paid up share capital) of Ishwari Healthcare Private Limited, a subsidiary, equivalent to 51.00% of the paid-up equity share capital of Ishwari Healthcare. Upon completion of the divestment, Ishwari Healthcare would cease to be a subsidiary of the Company.

Read more →📎 1 attachment
Page 1 of 2Next →